Pacira BioSciences, Inc. · Transaction May 6, 2021 · Filed Jun 23, 2021 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · PCRX
+0.16% · +$0.0400 · Vol 128.8K
Live · updated 12:31:27 ET
Pacira Biosciences Inc
Pharmaceuticals
$25.05
Follow $PCRX
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $PCRX by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredThu Oct 1 · last completed session · daily score · 19h old · PCRX
MethodologyPCRX
Pacira Biosciences Inc
Thu Oct 1 · last completed session · daily score · 19h old
Upper range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
70/ 100
Veridion Score
Upper range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Thu Oct 1 · last completed session · daily score · 19h old
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is PCRX moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Pacira Biosciences Inc
PHARMACEUTICAL PREPARATIONSListed since
2011
Employees
829
Country
US
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$25.04
Day high
$25.38
Day low
$24.66
Previous close
$25.01
52W high
$27.62
-9.30% from high
52W low
$19.16
70% of range
Market cap
$996.9M
P/E
68.57×
EPS
$0.3471
Beta
-0.16
Shares out
39.9M
Volume
128.8K
0.25× rel vol
Avg volume
524.9K
VWAP
$25.00
Price history computed in-house
1W
-0.28%
1M
-5.76%
3M
-1.34%
1Y
+1.91%
YTD
-3.21%
SMA 50 $25.28 · below
SMA 200 $23.90 · above
52W position 70%
PCRX overview
Related filings and maps
Public disclosures
Congress activity in PCRX
Official filing ↗
Pacira BioSciences, Inc. · Transaction Apr 20, 2021 · Filed Jun 12, 2021 · $1,001 to $15,000
PCRX · Transaction Jan 25, 2021 · Filed Aug 26, 2021 · $1,001 to $15,000
Pacira BioSciences, Inc. · Transaction Jan 15, 2021 · Filed Mar 5, 2021 · $1,001 to $15,000
Pacira BioSciences, Inc. · Transaction Nov 2, 2020 · Filed Mar 5, 2021 · $1,001 to $15,000
Federal contracts
PCRX contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for PCRX in this window.
Lobbying spend
PCRX lobbying filings, year to date.
Registered lobbying filings matched to Pacira Biosciences Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for PCRX in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for PCRX.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.